Ignite Creation Date:
2024-05-06 @ 2:06 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04219319
Status:
TERMINATED
Last Update Posted:
2022-08-16
First Post:
2019-11-20
Brief Title:
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4 T-cell Lymphoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
A Phase I Multicenter Study to Evaluate the Safety Tolerability and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4 T Lymphocyte Tumor Patiens
Status:
TERMINATED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Both the sponsors and collaborator are considering terminating the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase I Multicenter study to evaluate the safety tolerability and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4T Lymphocyte Tumor Patients
Detailed Description:
This is an open dose escalationdose extension study of LCAR-T2C CAR-T cells administrered to patients with T lymphocyte tumor The aim of the study is to evaluate the safety tolerability and efficacy of LCAR-T2C CAR-T cells The auto-CAR-T cells will be infused in single-dose
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None